Alberto Ocana: CDK12 inhibitor for the treatment of colorectal cancer
Alberto Ocana shared on LinkedIn:
“Dear community,
For those interested in nanomedicine, I will like to share our last publication in which we explore a new liposomal formulation to encapsulate a CDK12 inhibitor for the treatment of colorectal cancer. Improving the delivery of novel agents is a main task in cancer research. Thanks to Universidad de Castilla-La Mancha Professor Carlos Alonso and Professor Ivan Bravo for their work in nanotechnology and biosensors and CRIS Cancer Foundation and IdISSC for their support”
Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation
Authors: Cristina Díaz-Tejeiro, María Arenas-Moreira, Adrián Sanvicente, Lucía Paniagua-Herranz, Pilar Clemente-Casares, Ivan Bravo, Carlos Alonso-Moreno, Cristina Nieto-Jiménez, Alberto Ocaña
Source: Alberto Ocana/LinkedIn
Alberto Ocana MD, PhD is the Director of the CEU-START-INTHEOS Chair of Molecular Cancer Therapy at CEU Educational Group. He is also the Director preclinical research phase I program START, at Hospital Fundacion Jimenez Diaz. Previously, he was a professor at Complutense University of Madrid.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023